Drug intelligence / Profile preview

NCE2

Development stage: Preclinical
Lead developer: Epirium Bio
Modality: Small Molecules
Administration: Oral

Overview

NCE2 is a preclinical-stage small molecule therapeutic being developed by Epirium Bio for the treatment of neuromuscular diseases. Administered orally, NCE2 is part of Epirium's proprietary platform focused on mitochondrial biogenesis and tissue regeneration. The compound is designed to address the underlying bioenergetic deficits and mitochondrial dysfunction associated with various neuromuscular disorders, aiming to restore cellular function and promote tissue repair. As a new chemical entity (NCE) in the early stages of development, its specific molecular targets have not yet been publicly disclosed.

Targets

HPGD (15-hydroxyprostaglandin dehydrogenase)

Beyond the preview

Go deeper on NCE2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCE2.

Explore the full profile